Condition
Ocular Hypertension Clinical Trials
Studies of ocular hypertension, matched by condition name and medical subject headings. Start with those open to enrolment.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 282Corneal Transplantation, Glaucoma
Timing of Glaucoma Drainage Device With Boston Keratoprosthesis
Boston keratoprosthesis (KPro) is a piece of specialized plastic that replace sick cornea (transparent structure at the front of the eye) in patients who have failed or those who are expected to have poor results with traditional…
- Trial name
- GDD-KPro (NCT02084745)
- Testing
- Boston keratoprosthesis type 1, Glaucoma drainage device
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Macular Degeneration, Diabetic Retinopathy
Iopidine to Decrease Intraocular Pressure Rise After Injections
This is a prospective, randomized, controlled, open-label, single-site investigator-initiated clinical trial. A total of 120 participants will be randomized in a 1:1 ratio either to receive one drop of apraclonidine 1% ophthalmic…
- Conditions
- Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Glaucoma
- Trial name
- NCT07891910
- Testing
- Apraclonidine 1.0% ophthalmic solution
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Retina Consultants of Delmarva
Glaucoma
VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study
The purpose of this study is to determine if injections of aflibercept into the eye given at the end of the Ahmed tube surgery as well as at postoperative months one and two would improve eye pressure control compared to standard…
- Trial name
- NCT07891182
- Testing
- Aflibercept Injection, Ahmed Tube Surgery
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Miami
Glaucoma, Corneal Transplantation
Inflammatory Mediators of Glaucoma After Corneal Transplantation (AH-Tears)
Glaucoma is the most common threat to vision rehabilitation in patients with Boston keratoprosthesis type 1 (KPro) implantation.
- Conditions
- Glaucoma, Corneal Transplantation, Inflammation
- Trial name
- AH-Tears (NCT04339907)
- Testing
- Sampling of tears, Sampling of aqueous humor
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Glaucoma
A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage
Open-angle glaucoma is the most common type of glaucoma, a disease that damages the nerves in the eye and can lead to vision loss. Current treatments include eye drops, laser treatment, and surgery that help lower eye pressure.
- Trial name
- NCT07770685
- Testing
- ASP2767, Prophylactic Regimen A, Prophylactic Regimen B
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Glaucoma
A Study Evaluating the Safety and Efficacy of MINIject S+ in Subjects With Open Angle Glaucoma
This is a prospective, multi-center, international, cohort expansion study. Part 1 will be conducted in subjects with open angle glaucoma to identify the best insertion tool for MINIject S+.
- Trial name
- STAR VII (NCT07009236)
- Testing
- MIGS
- Where
- 5 sites in Honduras, United Kingdom
- Volunteers
- 60 people
- Sponsor
- iSTAR Medical
Glaucoma
Topical Insulin for Glaucoma
The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).
- Trial name
- TING1 (NCT05206877)
- Testing
- Insulin, 4 units, Insulin, 20 units, insulin, 4 units twice daily
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Stanford University
Glaucoma, Primary Open Angle
Evaluation the Safety and Effectiveness of the GORE GDI in Adult Subjects With Primary Open-angle Glaucoma in Whom Previous Medical and Surgical Treatment Have Failed.
Evaluation the Safety and Effectiveness of the GORE GDI in Adult Subjects With Primary Open-angle Glaucoma in Whom Previous Medical and Surgical Treatment Have Failed.
- Trial name
- NCT07880132
- Testing
- GORE Glaucoma Drainage Implant
- Volunteers
- 70 people
- Sponsor
- Gore Ophthalmic
Glaucoma
Glaucoma Screening to Enhance At-Risk Californians' Health
The vast majority of glaucoma cases in the United States go undetected and untreated until the late stages of the disease. Open-angle glaucoma is a progressive condition that is asymptomatic in its early to moderate stages and…
- Trial name
- G-SEARCH (NCT06854198)
- Testing
- Glaucoma screening with optical coherence tomography (OCT), color fundus photography, and tonometry, Educational Brochure
- Where
- 3 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Glaucoma, Glaucoma, Open-Angle
The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients
Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects.
- Conditions
- Glaucoma, Glaucoma, Open-Angle, Glaucoma; Drugs, Droopy Eyelid
- Trial name
- NCT04007276
- Testing
- brimonidine tartrate ophthalmic solution 0.025%, sterile balanced saline solution
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Tulane University
Completed, with results posted
All 370Open Angle Glaucoma, Ocular Hypertension
A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)
To assess efficacy, and safety of a single sustained release dose of the OTX-TIC drug product (2 travoprost dose strengths) in subjects with Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
- Trial name
- NCT05335122
- Testing
- OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg
- Where
- 30 sites in United States
- Volunteers
- 83 people
- Sponsor
- Ocular Therapeutix, Inc.
Glaucoma
A Study to Evaluate the Clinical Performance of VeriSee GLC for Screening of Glaucoma Suspect Using Color Fundus Images
The goal of this observational study is to evaluate the clinical performance of VeriSee GLC for identifying glaucoma suspects using color fundus images in adult participants.
- Trial name
- NCT07550712
- Where
- Taiwan
- Volunteers
- 773 people
- Sponsor
- Acer Medical Inc.
Glaucoma
Comparison of Visual Field Assessments Between Three Perimeters
A single center, prospective, randomized, comparative study of visual field assessments between the TEMPO, VisuALL, and HFA perimeters. Subjects will be assessed at 1 visit.
- Trial name
- NCT06539715
- Testing
- Visual field assessment
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Gainesville Eye Associates
Glaucoma
Baerveldt 350 vs Ahmed ClearPath 250 for the Treatment of Glaucoma
To compare the safety and efficacy of Baerveldt 350 and Ahmed ClearPath 250 tube shunts in lowering IOP in glaucoma patients.
- Trial name
- B350vsCP250 (NCT04542616)
- Testing
- Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- State University of New York at Buffalo
Primary Open Angle Glaucoma, Ocular Hypertension
Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure
The goal of this clinical trial is to test in patients with glaucoma and elevated pressure in the eye. The main questions it aims to answer are: • ability to lower pressure in the eye • safety in the eye and the body of patients…
- Trial name
- NCT06144918
- Testing
- SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0%
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Skye Bioscience, Inc.